Korro Bio, Inc.

KRROSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1703647

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	$14.1M	$37.0M
Research and Development Expense	$63.6M	$57.3M	$42.2M	$60.9M	$37.4M
Operating Expenses	$94.2M	$84.5M	$59.0M	$98.1M	$64.5M
Operating Income (Loss)	-$91.9M	-$84.5M	-$59.0M	-$84.0M	-$27.6M
Interest Expense	—	—	—	$764.0K	$0.00
Other Nonoperating Income (Expense)	$8.5M	$3.4M	$976.0K	-$266.0K	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$83.4M	-$81.1M	-$58.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$226.2M	$221.7M	$73.7M	$185.4M	$264.7M
Assets, Current	$131.5M	$172.7M	$57.1M	$134.7M	$225.1M
Cash and Cash Equivalents, at Carrying Value	$55.6M	$36.6M	$36.3M	$79.6M	$220.3M
Liabilities	$65.8M	$51.8M	$8.9M	$54.5M	$72.2M
Liabilities, Current	$15.0M	$19.5M	$8.7M	$11.4M	$26.6M
Long-term Debt, Excluding Current Maturities	—	—	—	—	—
Accounts Payable, Current	$4.0M	$7.3M	$2.6M	$2.7M	$5.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$60.1M	-$67.3M	-$53.6M	-$76.1M	-$45.2M
Net Cash Provided by (Used in) Investing Activities	-$123.3M	$11.2M	$11.1M	-$66.1M	$10.4M
Net Cash Provided by (Used in) Financing Activities	$69.4M	$187.8M	$18.0K	$1.4M	$56.7M
Payments to Acquire Property, Plant, and Equipment	$17.9M	$7.8M	$5.1M	$2.9M	$6.7M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)